Analysts’ Recent Ratings Updates for Qiagen (QGEN)

Qiagen (NYSE: QGEN) recently received a number of ratings updates from brokerages and research firms:

• 9/11/2026 – Qiagen was upgraded by Weiss Ratings from “hold (c-)” to “hold (c)”.
• 9/11/2026 – Qiagen had its “overweight” rating reaffirmed by Morgan Stanley.
• 9/9/2026 – Qiagen is now covered by UBS Group AG. They set a “neutral” rating and a $47.00 price target on the stock.
• 9/9/2026 – Qiagen had its price target lowered by UBS Group AG from $52.00 to $47.00. They now have a “hold” rating on the stock.
• 8/17/2026 – Qiagen was upgraded by Weiss Ratings from “sell (d+)” to “hold (c-)”.
• 8/10/2026 – Qiagen had its “neutral” rating reaffirmed by Citigroup Inc.. They now have a $45.00 price target on the stock, up from $38.00.
• 8/7/2026 – Qiagen was given a new $40.00 price target by Stifel Nicolaus.
• 8/7/2026 – Qiagen was given a new $40.00 price target by Barclays PLC. They now have an “equal weight” rating on the stock.
• 8/7/2026 – Qiagen had its price target raised by JPMorgan Chase & Co. from $45.00 to $50.00. They now have an “overweight” rating on the stock.
• 8/6/2026 – Qiagen had its “buy” rating reaffirmed by Jefferies Financial Group Inc.. They now have a $48.00 price target on the stock.

QIAGEN N.V. is a global provider of sample preparation, molecular testing and bioinformatics solutions used in life sciences research, molecular diagnostics and applied testing. The company develops technologies that help customers isolate and analyze DNA, RNA and other biological materials from blood, tissue and other samples.

Its offerings include laboratory instruments, consumables, assay kits and software. Key product areas include automated sample-processing systems, polymerase chain reaction (PCR) and digital PCR solutions, next-generation sequencing workflows, bioinformatics tools, and diagnostic tests such as QuantiFERON for tuberculosis testing and QIAstat-Dx for syndromic testing.